Quinsair
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Quinsair is an inhaled formulation of the antibiotic levofloxacin that is approved in the EU for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adults with cystic fibrosis. It is marketed in the EU as an oral solution for inhalation via nebulization, and is the only approved inhaled fluoroquinolone therapy for cystic fibrosis patients. Quinsair was first launched in Germany in April 2016 and is subsequently being rolled out throughout the rest of the EU.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Quinsair : Cystic fibrosis
LIST OF FIGURES
9 Figure 1: Quinsair for cystic fibrosis – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Quinsair for cystic fibrosis
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Quinsair for cystic fibrosis
13 Figure 4: Quinsair sales for cystic fibrosis across the five major EU markets, by country, 2016–25
LIST OF TABLES
6 Table 1: Quinsair drug profile
7 Table 2: Quinsair Phase IIb/III data in cystic fibrosis
14 Table 3: Quinsair sales for cystic fibrosis across the five major EU markets, by country ($m), 2016–25
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Kalydeco 
Sign up to the